Director, Peer-to-Peer Marketing
USA (Remote)
Posted 4 days ago
Job Summary
Own and execute the integrated peer-to-peer marketing strategy for cretostimogene across pre-launch, launch, and post-launch, driving speaker programs, congress planning, and cross-functional alignment.
- Lead the P2P strategy and speaker bureau initiatives
- Collaborate with HCP Marketing, Sales and Medical Affairs to ensure integrated execution
Job Description
Responsibilities
- Develop and own the integrated peer-to-peer marketing strategy for cretostimogene.
- Define the strategic role of P2P education within the overall brand and launch strategy.
- Identify the physician behaviors, knowledge gaps and adoption barriers that can most effectively be addressed through peer education.
- Develop distinct P2P strategies for pre-launch, launch and post-launch phases.
- Determine the appropriate balance of national, regional, local, in-person and virtual peer engagement.
- Ensure P2P strategy is tightly integrated with HCP Marketing, Sales, Medical Affairs and the broader customer engagement strategy.
- Develop an approach that can evolve as cretostimogene potentially expands into additional NMIBC patient populations.
- Develop the overall commercial speaker strategy and speaker bureau operating model.
- Identify the types, number and geographic distribution of speakers required to support launch.
- Partner with appropriate internal stakeholders to identify qualified potential speakers.
Requirements
- Bachelor’s degree in marketing, business administration or a related field or equivalent years of experience required.
- Ten (10+) years marketing experience.
- Significant experience in pharmaceutical marketing, with direct experience leading peer-to-peer or HCP marketing programs.
- Oncology experience strongly preferred; urology, bladder cancer or physician-administered oncology experience highly desirable.
- Demonstrated experience preparing for and/or executing a pharmaceutical product launch.
- Experience developing and managing commercial speaker bureaus and peer-to-peer programs.
- Strong understanding of HCP segmentation, targeting and customer engagement.
- Demonstrated ability to operate effectively within Regulatory, Legal and Compliance requirements.
- Up to 20-25% travel required.
- Work Authorization for US Applicants: Applicants must be authorized to work for any employer in the U.S. We are unable to sponsor or take over sponsorship of an employment visa at this time.
Preferred
- MBA or other graduate degree preferred
Benefits
- FULLY REMOTE WORK ENVIRONMENT
- REST AND RECHARGE BENEFITS - Unlimited Flexible Time Off
- HOLIDAYS - In 2026 we will observe 14 holidays
- RETIREMENT - 401K with 100% company Safe Harbor match up to 4% of base salary
- HEALTH (MEDICAL, DENTAL, VISION) - PPO & HDHP - Cigna/Principal
- HEALTH SPENDING ACCOUNTS - HSA (with Annual Company Contribution), FSA, FSA-DC
- ILLNESS & DISABILITY PROTECTION - Company Paid LTD Coverage + Voluntary Plans
- LIFE INSURANCE - Company Paid 2 x base salary + Voluntary Plans
- ADDITIONAL EXCLUSIVE BENEFITS - Voluntary Legal, Pet, Plus More
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life.Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).
Salaries
Posted range
$215K/yr – $235K/yr
Taken straight from the job posting.
Marketing Team
Funding
Funding History
- Dec 2024Post IPO Equity • $238M
- Aug 2023Series F • $105M
- Nov 2022Series E • $120M
Traffic Signals
Headcount Trend
News about CG Oncology Inc
Links
This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.
